Insider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells $196,236.12 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Melissa Epperly sold 4,938 shares of the stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $39.74, for a total transaction of $196,236.12. Following the completion of the transaction, the director owned 9,900 shares of the company’s stock, valued at approximately $393,426. This represents a 33.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roivant Sciences Stock Performance

NASDAQ ROIV traded up $0.41 during trading on Thursday, reaching $39.98. 7,603,971 shares of the company traded hands, compared to its average volume of 6,302,233. The stock’s 50 day moving average price is $36.04 and its two-hundred day moving average price is $31.89. The company has a market cap of $28.88 billion, a price-to-earnings ratio of -75.43 and a beta of 1.12. Roivant Sciences Ltd. has a 1-year low of $14.50 and a 1-year high of $42.50.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The business had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.06 million. Equities research analysts expect that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Bank of America reiterated a “neutral” rating on shares of Roivant Sciences in a research report on Friday, July 31st. Guggenheim raised their target price on Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a research note on Wednesday, September 9th. Leerink Partners set a $42.00 price target on Roivant Sciences in a report on Thursday, May 21st. UBS Group set a $55.00 price target on shares of Roivant Sciences in a research report on Wednesday, September 9th. Finally, Citigroup raised their price objective on shares of Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $41.42.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Allspring Global Investments Holdings LLC acquired a new position in Roivant Sciences in the first quarter valued at approximately $3,957,000. Jefferies Financial Group Inc. acquired a new stake in Roivant Sciences during the 4th quarter worth $76,272,000. Bank of America Corp DE grew its holdings in Roivant Sciences by 8.0% during the 1st quarter. Bank of America Corp DE now owns 3,163,821 shares of the company’s stock worth $87,638,000 after acquiring an additional 235,493 shares during the period. Nicholas Investment Partners LP raised its position in shares of Roivant Sciences by 13.9% during the 4th quarter. Nicholas Investment Partners LP now owns 279,856 shares of the company’s stock valued at $6,073,000 after acquiring an additional 34,235 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Roivant Sciences during the 4th quarter valued at $112,750,000. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs. The company concentrates on areas including immunology, dermatology, oncology and other specialty conditions, using a combination of internally developed programs, external licensing and strategic acquisitions.

Roivant organizes many of its drug-development activities through subsidiary companies known as “Vants.” These businesses are designed to advance individual therapeutic programs or groups of related assets, while Roivant provides operational, scientific and strategic support.